Company
Every investor coverage indicates participated in a round Arch Oncology raised.
Companies Arch Oncology acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Julie Cherrington | President and Chief Executive Officer | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Arch Oncology. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.